Ionis: Roche reports 43.1% proteinuria reduction in Phase 3 IgAN study
Ionis partner Roche announced Phase 3 IMAgINATION data showing investigational sefaxersen achieved a statistically significant 43.1% reduction in proteinuria relative to placebo at 37 weeks in adults with IgA nephropathy. Roche plans to share the data with health authorities, and the filing says Ionis is eligible for regulatory and sales milestone payments and tiered royalties on net sales of sefaxersen.
Key points
- Proteinuria reduction of 43.1% vs. placebo at 37 weeks (95% CI: 32.5 to 52.0; P<0.0001)
- Treatment effect consistent across all prespecified subgroups; no new safety signals reported
- Study enrolled 459 people and will continue as a blinded study to assess eGFR at week 105
- Roche will share data with health authorities; Ionis may receive regulatory and sales milestone payments and royalties
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.